Y-mAbs Therapeutics News and Activities

Y-mAbs Therapeutics is owned by Serb Pharmaceuticals. Serb Pharmaceuticals has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Serb Pharmaceuticals.

• Serb Pharmaceuticals has acquired Y-mAbs Therapeutics (posted on September 17 2025).
• Serb Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics  (posted on August 6 2025).

View the org chart displaying its 9 main executives

Most searched biographies at Y-mAbs Therapeutics

• Sharif Koep, Global Medical Affairs Director
• Barbara Blouw, Senior Director, Clinical Operations
• Gwen Thompson, Senior Director, Patient Services and Distribution

Popular executive movements at Y-mAbs Therapeutics

• Christopher Naylor, Senior Director, Head of Human Resources, has left the company  (posted on March 24 2026).
• Chad Lachapelle, Vice President, Sales and Operations, has left the company  (posted on March 24 2026).
• Norman Lafrance, Chief Development Officer, has left the company  (posted on November 19 2025).

Popular executive movements at Serb Pharmaceuticals

• Yelena Boitel has joined the company as Country Manager France  (posted on June 29 2026).
• Cecile Baradez has joined the company as Medical Science Liaisons Director  (posted on May 11 2026).
• Neha Chawla, who was Senior Director, Commercial Operations, is promoted to Executive Director, Commercial Operations  (posted on March 24 2026).

Create your alert
to follow the executive moves at Y-mAbs Therapeutics.

Serb Pharmaceuticals has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
• Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Y-mAbs Therapeutics

• Press Releases | Y-mAbs Therapeutics, Inc.
• Y-mAbs to Participate in Upcoming Investor Conferences in August | Y-mAbs Therapeutics, Inc.
• Press Releases | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast | Y-mAbs Therapeutics, Inc.
• Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments | Y-mAbs Therapeutics, Inc.
• Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer | Y-mAbs Therapeutics, Inc.
• Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting | Y-mAbs Therapeutics, Inc.
• View more press releases Close

Social media about Y-mAbs Therapeutics

• Y-mAbs Therapeutics on Wikipedia, Google News & Yahoo Finance
• Y-mAbs Therapeutics on LinkedIn, X (Twitter) & YouTube